Stopping metastasis
Targeting the HIF-1α-high, metastasis-driving subpopulation is more effective than targeting all cancer cells. A high-throughput screen of more than 12,000 compounds surfaced older statins as potent inhibitors of metastasis that act through a non-cholesterol, hypoxia-pathway mechanism; these are being developed as selective inhibitors of metastasis (SIM). With immunology collaborators, CD70-directed allogeneic CAR-NKT cells were built to target tumor, microenvironment, and alloreactive T cells together, as an off-the-shelf cell therapy for metastatic ccRCC.